Celgene ups dose and enrollment in mid-stage study of bb2121 in multiple myeloma [Seeking Alpha]
CELGENE (CELG)
Last celgene earnings: 10/31 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celgene.com
Company Research
Source: Seeking Alpha
Citing the totality of the clinical data, Celgene (NASDAQ: CELG ) has amended the protocol in its Phase 2 clinical trial, KarMMa , assessing CAR T candidate bb2121 in patients with relapsed/refractory multiple myeloma (MM). Specifically, the dose range has been increased to 15 - 45 x 10 7 CAR T-cells from 15 - 30 x 10 7 cells. Also, the enrollment target has been increased to up to 140 subjects. It has also amended the protocol in its Phase 1 study, CRB-401, evaluating bb2121 in relapsed/refractory MM. Enrollment will be increased by up to 20 subjects and the dose range will be the same as KarMMa. Celgene and licensor bluebird bio (NASDAQ: BLUE ) continue to expect regulatory approval for bb2121 in MM in 2020. CELG is up a fraction and BLUE is down a fraction after hours. Previously: Celgene and bluebird bio team up to develop and commercialize CAR T bb2121 (March 28) Previously: Celgene launches mid-stage study of CAR-T candidate bb2121 (Dec. 6, 2017
Show less
Read more
Impact Snapshot
Event Time:
CELG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELG alerts
High impacting CELGENE news events
Weekly update
A roundup of the hottest topics